What question did this study set out to answer?

May 30, 2026

Mortality trends of lymphoid and hematopoietic malignancies among US adults: A CDC WONDER– based demographic and regional analysis, 1999–2020.

Key Points

Analyze long-term mortality trends and sociodemographic patterns of lymphoid and hematopoietic malignancies in U.S. adults.
Utilized CDC WONDER database for mortality data (1999–2020)
Calculated crude and age-adjusted mortality rates per 100,000 using the 2000 standard population
Employed Joinpoint regression for trend analysis with APC and 95% confidence intervals.
1,217,470 deaths reported from 1999 to 2020; age-adjusted mortality rate declined by AAPC: -1.8% (95% CI: -2.0 to -1.6; p<0.000001).
Mortality rate was significantly higher in males (33.3) compared to females (20.05).
AAMR was highest in non-Hispanic whites (26.17) and increased significantly in the Midwest (27.61).

Abstract

e19101 Background: Malignant neoplasms of lymphoid and hematopoietic tissues are a major cause of oncology-related morbidity and mortality. The diverse pathological subtypes and intricate clinical progression of these malignancies can impact therapeutic management and long-term prognosis. This study analyzes long-term mortality trends and sociodemographic patterns of lymphoid and hematopoietic malignancies in U.S. adults. Methods: Mortality data (1999–2020) for adults ≥25 years with malignant neoplasms of lymphoid and hematopoietic tissues (C81–C96) were obtained from the CDC WONDER database. Crude and age-adjusted mortality rates (per 100,000) were calculated using the 2000 U.S. standard population. Trends were analyzed using Joinpoint regression (APC with 95% confidence intervals, p≤0.05), stratified by demographic and geographic categories. Results: Between 1999 and 2020, 1,217,470 deaths were reported, and the age-adjusted mortality rate declined significantly over the study period (AAPC: −1.8%; 95% CI: −2.0 to −1.6; p< 0.000001). This decline was characterized by a steady decrease from 1999 to 2008 (APC:− 1.9%; p < 0.001), a slower reduction from 2008-2012 (APC: −1.0%; p < 0.001), and then a pronounced decrease from 2012–2020 (APC: −2.1%; p < 0.001). The AAMR was significantly higher in males than in females (33.3 vs 20.05). The highest AAMR was observed among non-Hispanic whites (26.17), followed by non-Hispanic blacks (25.6). Crude mortality rates rose with age and were highest for those 65 and older (100.12), followed by those 45–64 (14.25) and those aged 25–44 (2.51). The AAMR increased significantly in the Midwest (27.61) and nonmetropolitan areas (26.87). AAMR varied considerably by state, ranging from 20.01 in Hawaii to 28.30 in West Virginia. Conclusions: Mortality due to lymphoid and hematopoietic malignancies showed a significant decrease over a period of twenty years. Particularly among males, the Midwest, NH White individuals, older adults, and non-metropolitan areas, indicating a higher burden of malignancy-related complications over time relative to other demographics. These results imply that specific interventions taken into consideration age-related risk factors and regional disparities are necessary to lower the burden of blood-related cancers. Mortality trends of lymphoid and hematopoietic malignancies among U.S. adults. Key Subgroup AAPC (%) 95% CI P-value Overall -1.83 -2.01 to -1.64 <0.000001 Male -1.70 -1.94 to -1.45 <0.000001 Female -2.13 -2.39 to -1.87 <0.000001 Age ≥85 years 4.25 4.01 to 4.48 <0.000001 Non- metropolitan areas -1.56 -1.64 to -1.48 <0.000001 Black or African American -1.59 -1.70 to -1.47 <0.000001 Asian or Pacific Islander -1.68 -2.27 to -1.09 <0.000001 Midwest Census Region -1.70 -1.79 to -1.61 <0.000001

Mark Helpful

Bookmark

Relay